Curis Beats On Per-Share Loss, But Dilution, A Slipping PCNSL Timeline And A Thin Cash Cushion Dominate The Quarter

Curis reported a third-quarter loss of $1.94 per share, beating the -$2.29 consensus by 15.3%. Earnings improved 80.2% year over year from a $9.86 loss. Revenue fell 100.0% to zero after the company sold its Erivedge royalties to Oberland in late 2025, removing the $3.2 million it booked a year earlier. The quality of the beat deserves scrutiny. The improvement is almost entirely arithmetic. Net loss actually widened to $8.1 million from $7.7 million, while weighted average shares rose to roughly 4.18 million from about 784,000. The per-share figures show a narrower loss, but in dollar terms the company lost slightly more money. For a clinical-stage company with no revenue, the central story is the race between data and dilution, not the earnings beat.

Beneath the headline, cost discipline was real. R&D expense fell to $5.6 million from $6.4 million, and G&A fell to $3.2 million from $3.7 million, both driven mainly by lower employee-related costs. Clinical costs and legal costs rose partly offsetting those savings. Operating loss still widened to $8.7 million from $6.9 million because the royalty revenue is gone. A $0.6 million other-income line, driven by a favorable change in the fair value of warrants from the January 2026 private placement, flattered the quarter. Over nine months, those same warrant effects contributed to $10.7 million of other expense and a $40.9 million net loss.

The balance sheet is the bigger concern. Cash stood at just $5.0 million at quarter-end. Accounts payable and accrued liabilities rose to $15.5 million, and stockholders' equity shrank to $2.6 million. Even with roughly $7.5 million in net proceeds from the October private placement, the release says operations are funded only into the first quarter of 2027. It also explicitly warns that Curis lacks sufficient cash for the next 12 months.

The call analysis frames the runway as "into 2027," without a cash balance, versus "into 2H 2027" on the prior two calls. Taken together with the release's "first quarter" language, the runway has clearly shortened. The release also flags the need to regain and maintain its Nasdaq listing, which adds another layer of risk.

Operationally, the call preserved a credible clinical narrative.

• **PCNSL data arrived early.** Updated TakeAim Lymphoma data came well ahead of the first-half 2027 update management had guided in the first quarter. BTKi-naïve patients showed an 86% ORR (6 of 7) against historical BTKi monotherapy response rates of 39%-67%. BTKi-experienced salvage patients showed a 26% ORR (10 of 39), or 33% among evaluable patients.
• **CLL enrollment ran ahead of plan.** The CLL study reached 12 patients across 11 sites, versus a prior goal of five dosed by mid-2026. Initial data are still expected in December.

Those are genuine execution wins, but bears have legitimate ammunition:

• **The salvage-line margin is thin.** The 26% salvage-line ORR sits only modestly above the roughly 20% hurdle management cited, with 10 to 15 more patients still needed.
• **The PCNSL timeline slipped.** Management now targets full enrollment by end of 2027 and an NDA filing in 2028, later than the earlier framing of a filing somewhere in the 2027 range.
• **The CLL readout looks less certain.** The CLL data venue is no longer pinned to ASH, and some patients will have only one or two cycles of treatment.
• **Other programs went quiet.** The AML and gastric programs went unmentioned, suggesting deprioritization.

The market has punished the dilution story severely. Shares opened at $1.83 after the August report and now trade at $0.59, a 67.7% decline. The stock sits nearly 93% below its 200-day moving average of $8.37, a gap that reflects heavy financing-driven dilution. Shares hit a 52-week low of $0.33 on October 16 and have since bounced 82% off that level. They remain about 72% below the quarter's $2.08 high, set on the day after the prior report. AVWAP trend readings remain negative.

Investor sentiment improved meaningfully, rising from -0.36 to -0.05, though it remains slightly negative. That shift likely reflects the early PCNSL data and imminent CLL catalyst more than the financial results.

The bottom line is that Curis delivered clinical progress, faster enrollment and lower operating expenses, but the per-share beat is a product of dilution rather than financial improvement. The December CLL readout is the next real test. Even a strong result arrives against a backdrop of a runway that only reaches into early 2027, a PCNSL filing pushed to 2028, and a capital structure that almost certainly requires further raises. Investors are weighing promising but early efficacy signals against the near-certainty of more dilution before any approval.

Read our earnings preview for Curis, Inc.: https://www.earningswhispers.com/article/CRIS/23009

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.